RADA16 for Adult Tonsillectomy
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Jul 1, 2025
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a product called RADA16 (also known by brand names like PuraStat®) can help improve recovery after adult tonsil removal surgery (tonsillectomy), specifically by reducing bleeding and pain afterward. Researchers will compare patients who receive RADA16 during their surgery with those who do not, to see if it makes a difference in healing and comfort.
Adults between 18 and 74 years old who are having a tonsillectomy and do not have certain other conditions—like previous tonsil surgery, additional throat surgeries, bleeding disorders, or ongoing opioid use—may be eligible to join. If you participate, you will have the tonsillectomy as planned, and then receive short surveys by email every two days for about two weeks to track your symptoms and recovery. This study is not yet recruiting participants, but if you qualify and decide to join, it could help doctors learn better ways to manage pain and bleeding after tonsil surgery.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Adults undergoing tonsillectomy (CPT codes)
- Exclusion criteria:
- • Patients undergoing adenoidectomy or uvulopalatopharyngoplasty in addition to tonsillectomy
- • Patients who have had prior tonsillectomy or tonsillotomy
- • Patient undergoing tonsillectomy with concern for malignancy
- • Patients who are on opioids chronically prior to surgery
- • Patients with an additional indication for pain management (i.e. unrelated to tonsillectomy)
- • Patients who have been diagnosed with a bleeding disorder or hematologic malignancy
- • Patients who are on anticoagulants
- The following at-risk populations:
- • Anyone under age 18
- • Pregnant women
- • Prisoners
- • Adults unable to consent (anyone lacking capacity)
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Wayne D Hsueh, MD
Principal Investigator
Rutgers University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported